NEWCASTLE UPON TYNE, UK, 26 May 2021. QuantuMDx has appointed Mirre de Noo, as a Non-Executive Director.
Mirre has over 20 years of experience in healthcare, strategy and innovation. As a life sciences and healthcare executive she has a track record of introducing and integrating novel state-of-the-art medical technologies in hospitals and with healthcare providers.
Currently, Mirre is the Chief Executive Officer of Reggeborgh Medical, a privately owned Dutch investment company and a Consultant Surgeon at Xpert Clinics, a private specialist medical service provider with 30 locations across the Netherlands.
Mirre serves as a board member and advisor at several life sciences and healthcare companies including Prescan and Amphera. She was also a member of the supervisory board of the national cancer screening programme in the Netherlands before joining Reggeborgh in 2019. Mirre has a PhD from Leiden University and qualified as a surgical oncologist and gastro-intestinal surgeon in 2013.
Neil Butler, Chairman of QuantuMDx, said: “On behalf of the Board, I would like to welcome Mirre to QuantuMDx. Mirre’s clinical knowledge, expertise and understanding of the use of diagnostics will be invaluable as we prepare to commercially launch our rapid point of care molecular diagnostic system, Q-POC™, later this year.”
Dr. Mirre de Noo, Non-Executive Director of QuantuMDx, said: “I am thrilled to be taking on this role within such a dynamic and promising company in molecular diagnostics. The explosion of knowledge about the structure of DNA is revolutionising for diagnostics and the treatment of many diseases. QuantuMDx has developed a high quality differentiated PCR-platform technology, Q-POC™, which could offer a solution to many healthcare problems now, and in the future.”
QuantuMDx Group is an ambitious company with a global vision of empowering the world to control and eradicate disease by making transformative, quality point-of-care diagnostic technologies universally accessible. QuantuMDx has operations and strategic partnerships in the United States, Asia, Australasia, Europe and Africa – keeping it at the forefront of molecular diagnostics. For more information go to: www.quantumdx.com
For media enquiries:
Debra Daglish, Marketing Communications Manager, QuantuMDx Group
For investor enquiries:
For more information:
Please email moc.xdmutnauq@ofni